🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 17 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 23/06/2000 | 51,01 | 51,25 | 46,50 | 48,44 | -3,37% | 9,31% | 1.351.600 |
| 22/06/2000 | 51,63 | 54,50 | 49,34 | 50,13 | -2,20% | 9,99% | 2.570.600 |
| 21/06/2000 | 48,44 | 52,50 | 48,13 | 51,25 | +3,60% | 9,03% | 1.942.400 |
| 20/06/2000 | 56,21 | 57,19 | 48,06 | 49,47 | -10,01% | 16,23% | 3.252.600 |
| 19/06/2000 | 45,50 | 55,00 | 45,44 | 54,97 | +22,15% | 21,02% | 4.114.600 |
| 16/06/2000 | 41,66 | 45,00 | 41,25 | 45,00 | +6,67% | 9,00% | 1.184.400 |
| 15/06/2000 | 41,88 | 42,34 | 39,63 | 42,19 | +3,05% | 6,49% | 1.418.800 |
| 14/06/2000 | 41,69 | 42,97 | 40,25 | 40,94 | -1,28% | 6,52% | 1.081.600 |
| 13/06/2000 | 40,31 | 41,47 | 39,50 | 41,47 | +3,59% | 4,88% | 529.400 |
| 12/06/2000 | 42,75 | 43,69 | 39,75 | 40,03 | -3,97% | 9,21% | 1.079.400 |
| 09/06/2000 | 41,06 | 44,59 | 39,69 | 41,69 | +3,57% | 11,95% | 1.638.400 |
| 08/06/2000 | 41,75 | 42,50 | 40,25 | 40,25 | -1,98% | 5,39% | 933.600 |
| 07/06/2000 | 40,75 | 41,81 | 40,63 | 41,06 | +5,46% | 2,91% | 1.793.000 |
| 06/06/2000 | 41,03 | 41,03 | 38,44 | 38,94 | -3,26% | 6,32% | 962.800 |
| 05/06/2000 | 41,59 | 43,09 | 39,00 | 40,25 | -3,01% | 9,84% | 829.600 |
| 02/06/2000 | 40,00 | 41,50 | 39,78 | 41,50 | +6,41% | 4,30% | 3.292.800 |
| 01/06/2000 | 37,25 | 39,81 | 37,06 | 39,00 | +5,58% | 7,38% | 1.306.200 |
| 31/05/2000 | 34,47 | 37,50 | 34,25 | 36,94 | +5,54% | 9,43% | 1.254.800 |
| 30/05/2000 | 32,00 | 35,97 | 32,00 | 35,00 | +8,95% | 12,40% | 1.168.600 |
| 26/05/2000 | 31,44 | 32,50 | 31,31 | 32,13 | +2,80% | 3,78% | 480.000 |
| 25/05/2000 | 30,88 | 31,88 | 30,06 | 31,25 | +2,67% | 5,87% | 751.400 |
| 24/05/2000 | 31,50 | 31,75 | 29,50 | 30,44 | -4,32% | 7,14% | 1.069.000 |
| 23/05/2000 | 32,00 | 34,50 | 31,50 | 31,81 | +0,59% | 9,38% | 861.400 |
| 22/05/2000 | 32,06 | 32,31 | 30,63 | 31,63 | -2,79% | 5,26% | 340.800 |
| 19/05/2000 | 34,56 | 34,72 | 31,19 | 32,53 | -7,22% | 10,22% | 489.600 |
| 18/05/2000 | 32,50 | 35,25 | 32,25 | 35,06 | +7,68% | 9,23% | 1.347.200 |
| 17/05/2000 | 32,72 | 33,88 | 31,59 | 32,56 | -2,07% | 6,97% | 654.200 |
| 16/05/2000 | 33,63 | 34,63 | 32,13 | 33,25 | -0,75% | 7,43% | 537.600 |
| 15/05/2000 | 30,50 | 33,59 | 30,50 | 33,50 | +8,94% | 10,14% | 633.800 |
| 12/05/2000 | 33,69 | 33,88 | 30,00 | 30,75 | -11,19% | 11,50% | 1.161.600 |